Metformin for Weight Loss: What It Can and Cannot Do

Metformin may help some people lose a modest amount of weight, but it is not an FDA-approved weight-loss medicine. In the original Diabetes Prevention Program (DPP), adults at high risk of diabetes lost an average of 2.1 kg (about 4.6 lb) with metformin plus standard lifestyle advice, compared with 0.1 kg with placebo plus the same advice. Follow-up varied and averaged 2.8 years, and these group averages do not predict your own result. Original DPP trial, 2002, Metformin prescribing information, section 1.

This guide is for adults preparing a conversation with a clinician, not choosing a dose or a weight-loss routine. The approved use of the extended-release product cited here is to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise. Using it specifically for weight loss is off-label, which the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) describes as using a medicine in a way that is different from what the FDA has approved. That choice needs an individual reason, a safety review, and a discussion of alternatives. Metformin prescribing information, section 1, NIDDK: off-label use.

What metformin does

Metformin is a type 2 diabetes medicine in a class called biguanides. MedlinePlus explains that it lowers the amount of glucose made by the liver and absorbed from food, and increases the body's response to insulin. It is not insulin, and it is not a GLP-1 receptor agonist. Those differences matter when you compare prescriptions, side effects, or expectations. MedlinePlus: metformin, why it is prescribed.

If you have seen it listed beside semaglutide on a telehealth website, the shared setting does not make the medicines interchangeable. Our guide to whether metformin is a GLP-1 explains that distinction in more detail.

Metformin comes as tablets, extended-release tablets, and a liquid, and their directions differ. The name, form, and instructions on your own prescription take priority over a weight-loss routine described online. The study results below are not instructions for changing products. MedlinePlus: metformin, how it is used.

How much weight loss did the original DPP report?

The original DPP randomly assigned 3,234 adults age 25 or older without diabetes who had elevated fasting and post-load blood glucose and met the study's body mass index (BMI) entry criteria. Post-load glucose means blood sugar measured after drinking a glucose solution for the test. BMI is calculated from weight and height; the participants' average BMI was 34.0, and their average age was 51. Original DPP trial, methods and Table 1.

The trial compared metformin plus standard lifestyle advice, placebo plus standard advice, and an intensive lifestyle program. Preventing diabetes was the main study question; weight change was also measured. Participants were followed for an average of 2.8 years, ranging from 1.8 to 4.6 years. Original DPP trial, NIDDK: DPP study overview.

Original DPP, 2002: adults without diabetes at high diabetes risk. Reported average losses from starting weight during variable follow-up, not individual predictions.

Pounds are rounded conversions of the published kilogram values, not additional study measurements. The figures describe each group's change from starting weight; they are not placebo-adjusted effects. Each published time-point average included only the people examined at that visit, and fewer people had reached the later visits: weight data were available for 3,064 people at 1 year and 1,510 at 3 years. Do not read the table as everyone's measured result at exactly 2.8 years. Original DPP trial, results and Figure 1.

The intensive lifestyle program, whose goals included at least 150 minutes of physical activity a week, produced more average weight loss than metformin. Original DPP trial, methods and results. If you are planning the activity side of your own routine, our guide to how many steps a day explains why your starting point and weekly minutes matter more than a single step target.

The DPP's best-known result is about diabetes, not weight. New cases of diabetes were less frequent with metformin than with placebo, and that reduction in diabetes incidence is sometimes misread as a share of body weight lost. It is a different outcome from the weight changes in the table. Original DPP trial, diabetes-incidence results.

These findings describe a population at high risk of diabetes, not everyone seeking weight treatment. They do not establish an FDA-approved obesity indication or a personal amount or timetable of weight loss. Ask your clinician whether that study population and treatment goal fit your situation.

What about people who already have type 2 diabetes?

The DPP enrolled people without diabetes. For adults with type 2 diabetes, the clinical studies section of the extended-release label reports small average weight changes. In a 16-week placebo-controlled study, average changes in the metformin groups ranged from a loss of 0.7 lb to a loss of 2.2 lb, close to the placebo group's average loss of 1.8 lb. In a 24-week study comparing metformin products without a placebo group, average weight rose by 0.9 to 1.1 lb. Metformin prescribing information, section 14.

Those studies reported blood sugar measures as their main results, and the label gives no statistical comparison for weight. If you take metformin for diabetes, an unchanged scale does not mean the medicine is failing at its approved job, which is blood sugar control.

Diabetes treatment, prevention research, and weight treatment are different questions

This table is a discussion aid, not a screening test. Your clinician may decide that a structured nutrition plan, another treatment, or investigation of a medical concern is the more useful next step.

If your question is about PCOS, the extended-release label cited here lists only type 2 diabetes, so prescribing it for PCOS is also off-label. Metformin prescribing information, section 1. Our guide to PCOS and belly weight explains what the 2023 international PCOS guideline says about metformin's role there.

How to judge progress without chasing daily fluctuations

Agree on what success means before treatment starts. If the medicine is prescribed for diabetes, glucose control and tolerability remain important even when your weight does not change. If weight is part of the goal, ask which trend to monitor and when you will reassess it.

Use comparable measurements rather than treating each day's reading as a verdict. Record the context of a change: a new medicine, vomiting or diarrhea, different eating patterns, or swelling. Fluid buildup can raise weight quickly, and MedlinePlus advises contacting your provider about any unexplained swelling. MedlinePlus: swelling.

You do not need to respond to a disappointing weigh-in by skipping meals, taking an extra tablet, or combining prescriptions yourself. MedlinePlus says to take metformin exactly as directed and to tell your doctor if you eat less or exercise more than usual, because this can affect your blood sugar; your doctor will give you instructions if that happens. MedlinePlus: metformin, how it is used and special precautions.

Safety checks that matter before and during treatment

Metformin can cause digestive side effects such as diarrhea, nausea, and upset stomach. The product's patient information says these generally go away after you take the medicine for a while, and asks you to tell your doctor if they bother you a lot, last for more than a few weeks, come back after going away, or start later in treatment. They are not a requirement for the medicine to work. The label also carries a boxed warning about lactic acidosis, a rare but potentially life-threatening buildup of lactic acid in the blood. Metformin prescribing information, boxed warning, section 6.1 and patient information, MedlinePlus: important warning.

The label also lists situations in which the product must not be used: severe kidney impairment, an allergy to metformin, and acute or chronic metabolic acidosis, including diabetic ketoacidosis. A clinician needs to assess these before prescribing. Metformin prescribing information, section 4.

The safety discussion should cover:

• Kidney function. Metformin is substantially cleared through the kidneys. Impaired kidney function can increase the risk of metformin accumulation and lactic acidosis. Kidney function is checked before and during treatment; ask your prescriber which checks and follow-up apply to you. Metformin prescribing information, section 5.1.
• Other lactic acidosis risk factors. Tell your prescriber about liver disease, excessive or binge alcohol use, and conditions involving low oxygen, such as acute heart failure. The label also identifies age 65 or older, certain other medicines, contrast imaging, surgery, and other procedures as risk factors. These are reasons for a clinical review, not a self-directed stopping schedule. Metformin prescribing information, boxed warning and section 5.1.
• Low blood sugar. The patient information says metformin rarely causes low blood sugar, also called hypoglycemia, by itself, but it can happen if you do not eat enough, if you drink alcohol, or if you take other medicines that lower blood sugar. The label also warns that combining metformin with insulin or an insulin secretagogue, such as a sulfonylurea, may increase that risk. Let the treating team decide whether any medicine needs adjusting. Metformin prescribing information, section 5.3 and patient information.
• Vitamin B12. Metformin can lower vitamin B12 levels, and the label notes that low levels may be associated with anemia. The label recommends periodic blood-count and vitamin B12 monitoring; ask your prescriber when your checks are due and how an abnormal result would be handled. Metformin prescribing information, section 5.2.
• Pregnancy or breastfeeding. Tell your clinician if you are pregnant, planning pregnancy, or breastfeeding. If you become pregnant while taking metformin, call your doctor. This calls for a treatment discussion, not an automatic medication change based on this article. MedlinePlus: metformin, special precautions.

Ask how to handle vomiting, diarrhea, fever, a serious infection, drinking much less fluid than usual, upcoming surgery, or an x-ray procedure that uses injected dye. MedlinePlus notes that you may need to stop metformin for a time in some of these situations, and that your doctor will tell you exactly when to stop and when to start again. Do not invent a stopping or restarting schedule from a blog. MedlinePlus: important warning.

The lactic acidosis warning is an exception to the usual advice not to change a medicine yourself. The product's patient information says to stop taking metformin and call your healthcare provider right away if you get possible symptoms of lactic acidosis: feeling very weak and tired, unusual muscle pain, trouble breathing, unusual sleepiness, unexplained stomach or intestinal problems with nausea and vomiting, or diarrhea, feeling cold, especially in your arms and legs, feeling dizzy or lightheaded, or a slow or irregular heartbeat. MedlinePlus gives a similar list that also includes stomach pain, decreased appetite, deep and rapid breathing, and a fast heartbeat. Because digestive symptoms appear on that list, do not dismiss new stomach symptoms that start later in treatment, or that come with weakness, breathing changes, or unusual sleepiness, as routine side effects. Do not wait to confirm lactic acidosis yourself. It is a medical emergency; call 911 for severe trouble breathing, collapse, or another emergency. A clinician should decide whether and when it is safe to restart. Metformin prescribing information, section 5.1 and patient information, MedlinePlus: important warning.

A useful conversation to have with your prescriber

Bring your medicine and supplement list and ask:

1. What health problem are we trying to treat, and is this use on-label or off-label?
2. What benefit would justify continuing treatment for me, and which alternatives should we compare?
3. Which kidney, blood sugar, or B12 checks apply to my conditions and other medicines?
4. What should I do if I am sick, cannot keep fluids down, or have a procedure scheduled?
5. What should I discuss if I am pregnant, planning pregnancy, or breastfeeding?
6. When will we review progress, and what would make us change the plan?

These questions help distinguish a considered treatment plan from a prescription sold around a weight-loss promise. NIDDK says you should feel comfortable asking whether a medicine you are prescribed is approved for treating overweight and obesity, and that you should learn all you need to know about a medicine before using it. NIDDK: off-label use.

Can metformin be compared directly with weight-loss injections?

Not by placing unrelated study results beside one another. Metformin, GLP-1 medicines, and other treatments have different indications, study populations, risks, and evidence. The DPP measured weight in adults at high risk of diabetes while asking a diabetes-prevention question, so a fair comparison starts with what is appropriate for the same person and goal.

NIDDK explains the role of prescription medicines for weight management, including weighing the likely benefits, possible side effects, your current health issues and other medicines, and your family's medical history. Metformin is not among the medicines that page lists as FDA-approved for long-term weight management. If you want to see how the studies of one approved weight-management medicine were set up and measured, our guide to Wegovy's label results reads that product's clinical studies section.

Other type 2 diabetes medicines raise the same weight question. Our guide to Jardiance and weight loss applies the same label-first reading to empagliflozin. For a tablet that is a GLP-1 medicine rather than a biguanide, see Rybelsus and weight loss.

Metformin is also not a shortcut to treating every possible reason for weight gain. NIDDK notes that some medicines and some health problems can contribute to weight gain, so if the pattern is unexpected, the useful next step may be a medication review or evaluation of another condition. NIDDK: factors affecting weight and health.

What this means if you are considering care

Keep the treatment decision separate from the appeal of a familiar generic pill. Ask for a clear rationale, follow-up, and an explanation of alternatives. You should understand what is being prescribed and why before agreeing to it.

Majesta Health is the publisher of this educational resource. This article does not recommend metformin for weight loss or establish eligibility for any prescription.

Educational information for adults, not an individual treatment plan. Sources were checked October 29, 2026, except the full DPP paper, which was read from a copy retrieved October 24, 2026; each source's access date is listed below. The DailyMed label applies to the named extended-release product in adults with type 2 diabetes, and its formulation-specific instructions are not generalized here. MedlinePlus metformin was last revised October 15, 2026. The DPP was published February 7, 2002, studied adults at high risk of diabetes, and reported group weight changes and diabetes incidence as different outcomes, with follow-up and the number of people examined at each visit varying.

Telehealth prescribing rules differ by state. Read the state-by-state guide.